華納藥廠(688799.SH):甘磷酰膽鹼原料藥獲得韓國原料藥品註冊證書
格隆匯5月9日丨華納藥廠(688799.SH)公佈,近日,公司全資子公司湖南華納大藥廠手性藥物有限公司(“手性藥物公司”)收到韓國食品藥品安全部(MFDS)簽發的原料藥品註冊證書,品種名稱為甘磷酰膽鹼(Choline Alfoscerate)。
甘磷酰膽鹼是機體內磷脂代謝的產物之一,也是重要的神經傳遞介質乙酰膽鹼的生物合成前體,具有降低高血脂、改善老年人的記憶和認知能力,治療阿爾茨海默症和修復腦神經損傷病等作用。
手性藥物公司甘磷酰膽鹼原料藥獲得韓國原料藥品註冊證書,標誌着其甘磷酰膽鹼原料藥獲得了韓國市場的准入資格,將對公司進一步擴大國際市場業務起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.